NovoCure Ltd

NVCR Nasdaq CIK: 0001645113

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Large accelerated filer
Country Jersey
Business Address NO. 4 THE FORUM, ST. HELIER, ,
Mailing Address NO. 4 THE FORUM, ST. HELIER, ,
Phone 44 (0)15 3475 6700
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024 FY

$605.22M
Revenue
-$168.63M
Net Income
$1.24B
Total Assets
$783.63M
Total Liabilities
$441.17M
Stockholders' Equity
$240.82M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment February 12, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report January 12, 2026 View on SEC
5 Annual insider ownership changes January 8, 2026 View on SEC
5 Annual insider ownership changes January 8, 2026 View on SEC
5 Annual insider ownership changes January 8, 2026 View on SEC
8-K Current report of material events December 1, 2025 View on SEC
SCHEDULE 13G/A Passive ownership amendment November 13, 2025 View on SEC

Material Events

8-K Legal Issue February 5, 2026
High Impact
  • NovoCure Ltd is pioneering electric field therapy (TTFields) for cancer, an innovative treatment.
  • The CMS revocation was due to an 'administrative process issue,' not issues with the effectiveness, safety, or quality of NovoCure's treatment.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.